FDA Fast-Tracks TREMFYA for Rare Kids' Diseases with Special Voucher
Published Date: 4/21/2025
Notice
Summary
The FDA just gave the green light to TREMFYA (guselkumab) for a rare pediatric disease, using a special priority review voucher. This means faster approval for treatments that kids with rare diseases really need. The approval happened on March 20, 2025, helping patients get access sooner and encouraging companies to develop more rare disease medicines.
Free Policy Watch
New rules are filed every week. Most people never see them.
Pick a topic. PRIA watches every federal rule and tells you when one hits your household.
Pick a topic to get started
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
TREMFYA Approved Using Priority Voucher
The FDA approved TREMFYA (guselkumab) on March 20, 2025, and that approval redeemed a Rare Pediatric Disease Priority Review Voucher. This approval is tied to the rare pediatric disease voucher program and represents an approved treatment for a pediatric indication as of March 20, 2025.
Voucher Program Incentivizes Drug Developers
The FDA issued a Rare Pediatric Disease Priority Review Voucher tied to the TREMFYA approval, reflecting the FD&C Act authority to award such vouchers to sponsors of approved rare pediatric disease products. The notice states the voucher program exists to be awarded and published when redeemed, which can encourage companies to develop rare pediatric disease medicines.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in